Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Semaglutide Reconstitution 5mg: BAC Water & IU Chart
articleA focused 5mg-vial reference for semaglutide reconstitution. Includes the two standard BAC water options (2mL and 2.5mL), the IU chart for every weekly dose from 0.25mg through 2.4mg, vial longevity math, the U-100 syringe capacity warning at the Wegovy maintenance dose, storage windows, and the U.S. regulatory context for compounded semaglutide in 2026.
Semaglutide Weight Loss: Results, Timeline & What to Expect
guidesHow much weight can you lose on semaglutide? STEP 1 trial data shows 14.9% mean body weight loss at 68 weeks, with 86.4% of participants losing at least 5%. This guide breaks down the clinical evidence, month-by-month timeline, real-world results, and what factors determine your outcome.
Compounded Semaglutide: Cost, Safety & How to Source (2026)
articleCompounded semaglutide costs a fraction of Ozempic or Wegovy but carries distinct risks. This guide covers the FDA regulatory landscape after the 2025 shortage resolution, how to source safely from legitimate pharmacies, dosing considerations, reconstitution, storage, and red flags to watch for.